This Drug Stock Has Crushed the S&P 500 Over the Last Decade

Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound posted explosive 2025 sales growth of 99% and 175%, but the article argues the stock is expensive at 39x earnings versus 23x for the average drug company. It highlights patent-expiration risk, intensifying GLP-1 competition from Novo Nordisk and Pfizer, and uncertainty around Lilly’s pipeline acquisitions. The piece is fundamentally bullish on the business but cautious on the stock’s valuation and long-term durability.

Analysis

The market is treating the GLP-1 franchise like a durable monopoly, but the more relevant lens is pricing a shrinking-duration cash flow stream with unusually high terminal risk. The first-order issue is not whether demand stays strong over the next few quarters; it’s whether today’s multiple already discounts peak share, peak mix, and a long runway before competitive substitution begins. In that setup, the stock can stay expensive for a long time, but the asymmetry shifts unfavorably once the marginal buyer starts anchoring on perfect execution.

The real second-order winner is not necessarily the obvious competitor with the best headline efficacy, but the set of companies that can monetize the category’s expansion without carrying the same patent overhang. NVO has the clearest relative benefit if it keeps converting pill convenience into earlier therapy adoption and broader physician willingness to prescribe; that is especially powerful if oral formulations reduce adherence friction. PFE is a lower-probability but higher-upside call option on the next delivery format shift, though timing risk is substantial. The more important competitive effect is that every credible entrant raises the probability of price compression, rebate escalation, and broader payer scrutiny across the class, which can compress economics even before exclusivity expires.

Near-term catalysts are mostly negative for the incumbent on a relative basis: any incremental trial data from rivals, any insurer pushback on reimbursement, or any signs of slowing refill velocity would matter more than absolute sales growth. The contrarian miss in the market is that “category growth” does not automatically translate into “winner keeps all” when the market becomes more crowded and the payers regain negotiating leverage. Over the next 6-18 months, multiple compression is a more plausible source of downside than a catastrophic fundamentals break.

This is a better expression as a relative-value trade than an outright bearish call. The stock can remain resilient if growth re-accelerates, but downside is increasingly tied to sentiment and multiple, while upside requires continued perfection plus pipeline execution. That is a poor risk/reward profile for new longs at this valuation regime.

Key Decisions for Investors

• Initiate a relative-value pair: long NVO / short LLY for 3-9 months. Rationale: NVO has the cleaner incremental catalyst path from convenience-led adoption, while LLY carries the higher expectation bar and more patent-duration risk. Target 10-15% relative outperformance; cut if LLY regains clear share lead on new data.
• Buy LLY downside via 3-6 month put spreads rather than outright shorting. This captures multiple compression risk without fighting the underlying growth trend; best if implied vol remains below realized and the stock re-rates on any competitive headline.
• Add tactical long PFE as a small-sized call-option expression only, 6-12 months. The trade is a low-probability optionality bet on pipeline execution in long-acting GLP-1 delivery, with asymmetric upside if the market starts paying for format innovation rather than just efficacy.
• Avoid initiating fresh long LLY at current valuation unless there is a 15-20% pullback or clearer evidence of sustained pricing power. The risk/reward is skewed by terminal exclusivity assumptions and a crowded competitive field.
• For existing LLY longs, sell covered calls into strength over the next earnings window to monetize elevated expectations. This converts some of the multiple risk into carry while retaining core participation if fundamentals continue to surprise.